ReviewBritish journal of haematology2014
How I treat children and adolescents with acute promyelocytic leukaemia.
Review in British journal of haematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Trial
- Improvement in Outcomes of Childhood Acute Myeloid Leukemia Treatment: A Survival Analysis at a Reference University Hospital in Rio de Janeiro, Brazil.Cancer reports (Hoboken, N.J.) · 2026Article
- Medication-induced lung disease in children.Pediatric radiology · 2026Review
- Treatment of Pediatric Acute Promyelocytic Leukemia with Retinoic Acid and Arsenic Trioxide along with Chemotherapy.Indian journal of pediatrics · 2024Article
- Clinical Characteristics and Treatment Outcomes of Childhood Acute Promyelocytic Leukemia in Korea: A Nationwide Multicenter Retrospective Study by Korean Pediatric Oncology Study Group.Cancer research and treatment · 2022Article
- Opportunities and Challenges in Drug Development for Pediatric Cancers.Cancer discovery · 2021Review
- Pediatric Fibrinogen PART II-Overview of Indications for Fibrinogen Use in Critically Ill Children.Frontiers in pediatrics · 2021Review
- [How I treat children with acute promyelocytic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- Management of patients with acute promyelocytic leukemia.Leukemia · 2018Review
- Application of GATA-3 gene marker in the detection of hematologic disorders in children.Experimental and therapeutic medicine · 2018Article
- Pediatric Acute Promyelocytic Leukemia Presenting to the Emergency Department as Refusal to Ambulate.Case reports in emergency medicine · 2018Article
- Acute Promyelocytic Leukemia in Children: A Single Centre Experience from Turkey.Mediterranean journal of hematology and infectious diseases · 2018Article
- A Multicenter Experience from Lebanon in Childhood and Adolescent Acute Myeloid Leukemia: High rate of Early Death in Childhood Acute Promyelocytic Leukemia.Mediterranean journal of hematology and infectious diseases · 2015Article
- Acute Promyelocytic Leukemia (APL): Comparison Between Children and Adults.Mediterranean journal of hematology and infectious diseases · 2014Review
- Cytogenetic abnormalities, WHO classification, and evolution of children and adolescents with acute myeloid leukemia.Hematology, transfusion and cell therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Acute promyelocytic leukaemia (APL) is a rare subtype of acute myeloid leukaemia. The outcome of paediatric APL has improved substantially over the past 20 years; cure rates above 80% are expected when all-trans retinoic acid (ATRA) is given with anthracycline-based regimens. The presenting features of paediatric APL may include severe bleeding and thrombotic complications, which contribute to the high early death rate. The incidence of leucocytosis and the microgranular subtype is greater in paediatric than adult APL, and children experience greater ATRA-related toxicity. It is crucial to begin ATRA therapy and intensive platelet and fibrinogen replacement on first suspicion of APL. Recent risk-adapted therapeutic trials have shown that patients at greater risk of relapse benefit from the introduction of high-dose cytarabine during consolidation. Combination therapy with ATRA and arsenic trioxide provides very effective frontline treatment and may reduce the need for subsequent anthracycline therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.